



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

33rd Edition

M100

Performance Standards for Antimicrobial Susceptibility Testing

This document includes updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards M02, M07, and M11.

A CLSI supplement for global application.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Performance Standards for Antimicrobial Susceptibility Testing

James S. Lewis II, PharmD, FIDSA
Melvin P. Weinstein, MD
April M. Bobenchik, PhD, D(ABMM),
MLS(ASCP)
Shelley Campeau, PhD, D(ABMM)
Sharon K. Cullen, BS, RAC
Tanis Dingle, PhD, D(ABMM), FCCM
Marcelo F. Galas, BSc
Romney M. Humphries, PhD, D(ABMM), FIDSA

Thomas J. Kirn, Jr., MD, PhD
Brandi Limbago, PhD
Amy J. Mathers, MD, D(ABMM)
Virginia M. Pierce, MD, FIDSA
Sandra S. Richter, MD, D(ABMM), FIDSA
Michael Satlin, MD, MS
Audrey N. Schuetz, MD, MPH, D(ABMM)
Susan Sharp, PhD, D(ABMM), F(AAM)
Patricia J. Simner, PhD, D(ABMM)

Abstract

The data in the tables are valid only if the methodologies in CLSI documents M02,¹ M07,² and M11³ are followed. These standards contain information about disk diffusion (M02¹) and dilution (M07² and M11³) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in M02,¹ M07,² and M11.³ Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing*. 33rd ed. CLSI supplement M100 (ISBN 978-1-68440-170-3 [Print]; ISBN 978-1-68440-171-0 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2023.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

**If you or your organization is not a member and would like to become one,
or to request a copy of the catalog, contact us at:**

P: +1.610.688.0100; **F:** +1.610.688.0700; **E:** customerservice@clsi.org; **W:** www.clsi.org.

Copyright ©2023 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*. 33rd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2023.

Previous Editions:

December 1986, December 1987, December 1991, December 1992, December 1994, December 1995, January 1997, January 1998, January 1999, January 2000, January 2001, January 2002, January 2003, January 2004, January 2005, January 2006, January 2007, January 2008, January 2009, January 2010, June 2010, January 2011, January 2012, January 2013, January 2014, January 2015, January 2016, January 2017, January 2018, January 2019, January 2020, March 2021, February 2022

Correction:

March 2023

M100-Ed33
ISBN 978-1-68440-170-3 (Print)
ISBN 978-1-68440-171-0 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Volume 43, Number 3

Committee Membership

Subcommittee on Antimicrobial Susceptibility Testing

James S. Lewis II, PharmD, FIDSA
Chairholder
Oregon Health and Science University
USA

Romney M. Humphries, PhD,
D(ABMM), FIDSA
Vanderbilt University Medical Center
USA

Sandra S. Richter, MD,
D(ABMM), FIDSA
Mayo Clinic, Jacksonville
USA

Melvin P. Weinstein, MD
Vice-Chairholder
Robert Wood Johnson University
Hospital
USA

Thomas J. Kirn, Jr., MD, PhD
Rutgers Robert Wood Johnson
Medical School
USA

Michael Satlin, MD, MS
Weill Cornell Medicine
USA

Sharon K. Cullen, BS, RAC
Beckman Coulter, Inc.,
Microbiology Business
USA

Brandi Limbago, PhD
Centers for Disease Control and
Prevention
USA

Audrey N. Schuetz, MD, MPH,
D(ABMM)
Mayo Clinic, Rochester
USA

Tanis Dingle, PhD, D(ABMM), FCCM
Alberta Precision Laboratories -
Public Health Laboratory
Canada

Amy J. Mathers, MD, D(ABMM)
University of Virginia Medical Center
USA

Susan Sharp, PhD, D(ABMM),
F(AAM)
Copan Diagnostics, Inc.
USA

Marcelo F. Galas, BSc
Pan American Health Organization
USA

Virginia M. Pierce, MD, FIDSA
University of Michigan Medical School
USA

Patricia J. Simner, PhD, D(ABMM)
Johns Hopkins University School of
Medicine, Department of
Pathology
USA

Acknowledgment

CLSI and the Subcommittee on Antimicrobial Susceptibility Testing gratefully acknowledge the following volunteers for their important contributions to the revision of this document:

April M. Bobenchik, PhD, D(ABMM),
MLS(ASCP)
Penn State Health Milton S. Hershey
Medical Center
USA

Shelley Campeau, PhD, D(ABMM)
Scientific and Medical Affairs
Consulting, LLC
USA

Melissa Jones, MT(ASCP), CLS
DUHS Clinical Laboratories
USA

Jean B. Patel, PhD, D(ABMM)
Beckman Coulter
USA

Patricia J. Simner, PhD, D(ABMM)
Johns Hopkins University School of
Medicine, Department of Pathology
USA

Barbara L. Zimmer, PhD
Beckman Coulter, Inc.
USA